Skip to content

General Control

Multi-gene epigenetic editors for age-related disease

Raised to date

$14.8M

of $16.1M offered across 1 Form D filing

Still open
$1.3M
Investors
15
Last filed
Apr 30, 2026

About

General Control is a San Francisco biotech developing programmable epigenetic editors that raise or lower expression of several genes at once without changing DNA sequence. Its focus is multifactorial age-related diseases such as Alzheimer's and sarcopenia. The pipeline is early-stage, with programs in activation and silencing and a platform collaboration with Novo Nordisk announced in November 2025.

Multiplexed, durable and reversible epigenetic editing aimed at coordinated control of several genes in a single therapy.

Funding

  • EquityFiled Apr 30, 2026Form D
    $14.8M/ $16.1M

Product

Programmable epigenetic editors

Epigenetic therapeutics

Epigenetic editing therapies, including miniature epigenetic activators that stably upregulate genes at native loci and chromatin-level silencers, designed to act on multiple genes in one medicine.

  • Multiplex gene activation and silencing
  • Durable and reversible gene-expression control
  • Miniature epigenetic activators for native loci

Built for

Patients with complex age-related and chronic diseases, and pharma partners

People on file